of early detection of gastric cancer, and the progress in endoscopic techniques has replaced surgical resection with ER for EGCs. 4 ER has shown many advantages in terms of quality of life and short-and long-term clinical outcomes. 5 As the proportion of ER in the gastric neoplasms has increased, issues regarding synchronous or metachronous multiple gastric neoplasms after treatment have become more important. In previous studies, synchronous gastric cancers accounted for 6%-14% of all gastric cancer cases. 6, 7 Multiple gastric cancers have several clinicopathologic features including older age, well differentiated tumors, and early stage tumors. 8 They have prognosis similar to that of single gastric cancers. However, the presence of synchronous multiple gastric cancers is known to increase the risk of missing remnant gastric lesion(s), especially when the patient has severe mucosal atrophy and/or advanced intestinal metaplasia. Thus, more frequent follow-up endoscopies are necessary to detect the missing tumors in the first 1-2 years after the ER of gastric neoplasms in these patients. Contrary to surgical resection, ER can preserve the entire stomach, and the gastric mucosa of a gastric cancer patient possesses a higher risk of gastric carcinogenesis than that of normal healthy individuals (field cancerization). 9 The rate of metachronous gastric neoplasms has been reported to be 4%-10% during 5-year follow-up. 4, 7, 10 Therefore, long-term endoscopic surveillance after ER is crucial for the early diagnosis of metachronous gastric neoplasms and minimally invasive curative treatment of these lesions. Based on this background, Lee et al., comprehensively investigated the clinical implications of synchronous and metachronous multiple gastric tumors after ER of gastric tumors. 11 Although it was a single-center, retrospective study, 11 some of the results of the study need to be addressed in detail.
First, in this study, the incidence of synchronous and metachronous gastric cancers (15.5%) was a bit higher than that of previous studies. This is probably because the majority of the study population was elderly men (mean age at diagnosis, >65 years); thus, most of them might have severe atrophy or intestinal metaplasia at diagnosis. Severe atrophy and/or metaplasia are regarded as risk factors for synchronous and metachronous gastric neoplasms after ER of gastric neoplasms. In addition, Helicobacter pylori eradication has been reported to reduce the risk of metachronous gastric neoplasms. 12 Recently, a Korean prospective, double-blind, placebo-controlled, randomized trial reported that patients with EGC who received H. pylori treatment had lower rates of metachronous gastric cancer than patients who received placebo (hazard ratio, 0.50). 13 In this study, however, the occurrence of metachronous gastric neoplasms was not different between the groups according to H. pylori eradication. It may be also attributable to the presumably higher incidence of severe atrophy or intestinal metaplasia in this study than in previous studies. The effect of H. pylori eradication could be attenuated by severe atrophy and intestinal metaplasia. In previous studies, severe mucosal atrophy (either endoscopic biopsy or pepsinogen I/II ratio <3.0), but not H. pylori infection status at the time of diagnosis, was an independent risk factor for metachronous gastric cancer after ER of EGCs. 14 Thus, long-term surveillance is essential for those with severe atrophy or intestinal metaplasia even after successful H. pylori eradication. Finally, in this study, more than 50% of the neoplasms in patients with multiple gastric lesions developed in the same longitudinal location of the stomach during follow-up. Interestingly, most of the the newly detected lesions showed the same endoscopic and histopathological types as those of the primary lesions in this study. However, a previous study reported that most metachronous gastric adenocarcinomas occurred at sites other than the previous resection sites.
